If you have been reading about AOD-9604 and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-07-13. Numbers and descriptions here follow the published literature rather than marketing material.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine | Major agencies have not authorized it for therapeutic use. |
| Anti-doping status | Prohibited in sport | Listed among peptide hormones and related substances. |
| Primary research area | Metabolic and body-composition effects | Studies often examine fat mass or lipid markers. |
| Human evidence | Limited and mixed | Public data do not establish clinical efficacy. |
| Analytical detection | LC-MS and immunoassays | Methods vary in sensitivity and validation. |
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Quality control for AOD-9604 involves verifying identity, purity, and concentration. Suppliers may provide a certificate of analysis listing HPLC purity and mass spectrometry data. Independent verification is advised because peptide products can vary in quality. Researchers should check for counterions, residual solvents, and microbial contamination. Proper documentation supports reproducibility and safety in laboratory studies. When sourcing, institutions often require third-party testing and detailed chain-of-custody records. These steps help ensure that experimental results are attributable to the peptide rather than impurities.
Analytical characterization of AOD-9604 typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and identity. Mass spectrometry provides confirmation of molecular mass, while amino acid analysis can verify composition. These methods are standard for peptide research chemicals. Because the peptide lacks a distinct chromophore, detection often relies on ultraviolet absorbance at 214 nm or mass spectrometric response. Laboratories may also use capillary electrophoresis for separation. For example, size-exclusion chromatography can detect aggregates.
Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.
=== Phosphorus-33 === Phosphorus-33 is a radioactive isotope of phosphorus; it is produced from sulfur-33. is a pure β-emitter, like 32P, and can be used as an alternative to it in research in molecular biology. Indeed, its longer half-life and especially its lower decay energy make its manipulation simpler in the laboratory. In the medical field, 33P has been used in the treatment of arterial stenosis but is no longer indicated at this time.
Luseogliflozin (trade name Lusefi) is a pharmaceutical drug (an SGLT2 inhibitor) used for the treatment of type 2 diabetes mellitus. It was approved for use in Japan in 2014. In a meta-analysis involving data from 10 randomized controlled trials (1304 patients), Dutta et al. demonstrated the good glycaemic efficacy (mean glycated hemoglobin reduction of -0.76% and mean fasting glucose reduction of -26.69mg/dl) and safety of luseogliflozin 2.5mg/day as compared to placebo. Additional benefits include significant reduction in systolic blood pressure (-4.19 mm Hg), serum triglycerides (-12.60mg/dl), uric acid (-0.48mg/dl) and alanine aminotransferase (-4.11 IU/L) as compared to placebo, highlighting the beneficial impact on the different aspects of metabolic syndrome.
=== Low BMD === Bone Mineral Density (BMD) tends to peak at a young age. When children are younger, they start building up their BMD through their nutrition and through exercise. BMD peaks at around 12.5 years old for girls and around 14 years old for boys. It could be caused by a deficiency in calcium or Vitamin D. Calcium is the main nutrient for bone health. It aids in the structure and density of the bone. Low BMD could be caused by the children not getting the proper exercise for adequate bone growth. Researchers suggest that children should get 20 minutes of vigorous activity 3 to 5 days a week to promote an increase in BMD. Jumping for about 5 minutes a day also stimulates an increase in BMD. Researchers did a 10-year study on the effects of vigorous intensity activity and their bone health/strength. They studied 300 boys and girls. They found that in boys going through puberty (ages 11-13), they experienced a greater bone mass growth. Their bone mass increased during this time because their bones are not ready for the mechanical stress from them growing. However, that is how the bones grow stronger and why their BMD increases. Too much stress on the bones could cause BMD to decrease. Low BMD is dangerous because it can cause disorders inside the bone as the children grow and get older. These disorders can cause the bone to ossify, become brittle, fragile, more easily prone to fractures, and weak. Some of these disorders include osteopenia, osteoporosis, and scoliosis. Scoliosis is very common in children. Low BMD plays a role in the child's scoliosis.
Sources: en.wikipedia.org
=== Zeolites === Zeolites are natural or synthetic crystalline aluminosilicates, which have a repeating pore network and release water at high temperature. Zeolites are polar in nature. They are manufactured by hydrothermal synthesis of sodium aluminosilicate or another silica source in an autoclave followed by ion exchange with certain cations (Na+, Li+, Ca2+, K+, NH4+). The channel diameter of zeolite cages usually ranges from 2 to 9 Å. The ion exchange process is followed by drying of the crystals, which can be pelletized with a binder to form macroporous pellets. Zeolites are applied in drying of process air, CO2 removal from natural gas, CO removal from reforming gas, air separation, catalytic cracking, and catalytic synthesis and reforming. Non-polar (siliceous) zeolites are synthesized from aluminum-free silica sources or by dealumination of aluminum-containing zeolites. The dealumination process is done by treating the zeolite with steam at elevated temperatures, typically greater than 500 °C (930 °F). This high-temperature heat treatment breaks the aluminum-oxygen bonds and the aluminum atom is expelled from the zeolite framework.
Russia's Federal Security Service (FSB) claimed to have intercepted 70 kilograms of RDX, an RPG-7 and other bomb-making material at a border crossing in Pskov Oblast from Latvia. Originating from Ukraine, the paperwork indicated that it travelled through several EU countries before reaching the Russian border. The weapons were discovered hidden in Orthodox religious icons and paraphernalia.
=== Quantitative analysis === Quantitative approach requires large number of grain analyses within a sample rock in order to represent the overall detrital zircon population statistically (i.e. the total number of analyses should achieve an appropriate level of confidence). Because of the large sample size, secondary ion mass spectrometry (SIMS) and laser ablation-inductively coupled plasma mass spectrometry (LA-ICPMS) are used instead of thermal ionization mass spectrometry (TIMS). In this case, BSE and CL imagery are applied to select the best spot on a zircon grain for acquiring reliable age.
== Later research == A 1991 review by a cold fusion proponent had calculated "about 600 scientists" were still conducting research. After 1991, cold fusion research only continued in relative obscurity, conducted by groups that had increasing difficulty securing public funding and keeping programs open. These small but committed groups of cold fusion researchers have continued to conduct experiments using Fleischmann and Pons electrolysis setups in spite of the rejection by the mainstream community. The Boston Globe estimated in 2004 that there were only 100 to 200 researchers working in the field, most suffering damage to their reputation and career. Since the main controversy over Pons and Fleischmann had ended, cold fusion research has been funded by private and small governmental scientific investment funds in the United States, Italy, Japan, and India. For example, it was reported in Nature, in May, 2019, that Google had spent approximately $10 million on cold fusion research. A group of scientists at well-known research labs (e.g., MIT, Lawrence Berkeley National Lab, and others) worked for several years to establish experimental protocols and measurement techniques in an effort to re-evaluate cold fusion to a high standard of scientific rigor. Their reported conclusion: no cold fusion.
Sources: en.wikipedia.org
The eating habits of Komodo dragons follow a hierarchy, with the larger animals generally eating before the smaller ones. The largest male typically asserts his dominance and the smaller males show their submission by use of body language and rumbling hisses. Dragons of equal size may resort to "wrestling". Losers usually retreat, though they have been known to be killed and eaten by victors. The Komodo dragon's diet varies depending on stage of growth. Young Komodo dragons will eat insects, birds and bird's eggs and small reptiles, while larger Komodo dragons (typically over 20 kg (44 lb)) prefer large ungulate prey, such as Javan rusa deer, wild pigs and water buffalo. Occasionally, they attack and bite humans. Sometimes they consume human corpses, digging up bodies from shallow graves. This habit of raiding graves caused the villagers of Komodo to move their graves from sandy to clay ground, and pile rocks on top of them, to deter the lizards. Dwarf species of Stegodon (a proboscidean related to living elephants) are suggested to have been a primary prey item of the Komodo dragon during the Pleistocene, prior to the introduction of their modern ungulate prey, which were only introduced to the islands in the Holocene, around 10-7,000 years ago. The Komodo dragon drinks by sucking water into its mouth via buccal pumping (a process also used for respiration), lifting its head, and letting the water run down its throat.
Vitamin B4: can refer to the distinct chemicals choline, adenine, or carnitine. Choline is synthesized by the human body, but not sufficiently to maintain good health, and is now considered an essential dietary nutrient. Adenine is a nucleobase synthesized by the human body. Carnitine is an essential dietary nutrient for certain worms, but not for humans. Vitamin B8: adenosine monophosphate (AMP), also known as adenylic acid. Vitamin B8 may also refer to inositol. Vitamin B10: para-aminobenzoic acid (pABA or PABA), a chemical component of the folate molecule produced by plants and bacteria, and found in many foods. It is best known as a UV-blocking sunscreen applied to the skin, and is sometimes taken orally for certain medical conditions. Vitamin B11: pteroylheptaglutamic acid (PHGA; chick growth factor). Vitamin Bc-conjugate was also found to be identical to PHGA. Derivative of folate ("pteroylmonoglutamic acid" in this nomenclature). Vitamin B13: orotic acid. Vitamin B14: cell proliferant, anti-anemia, rat growth factor, and antitumor pterin phosphate, named by Earl R. Norris. Isolated from human urine at 0.33ppm (later in blood), but later abandoned by him as further evidence did not confirm this. He also claimed this was not xanthopterin. Vitamin B15: pangamic acid, also known as pangamate. Promoted in various forms as a dietary supplement and drug; considered unsafe and subject to seizure by the US Food and Drug Administration. Vitamin B16: dimethylglycine (DMG) is synthesized by the human body from choline.
== Abstracting and indexing == The journal is abstracted and indexed in Biological Abstracts, Chemical Abstracts, Current Contents/Life Sciences, EMBiology, Food Science and Technology Abstracts, MEDLINE, Science Citation Index and Scopus.
==== Characterization of synthetic carbon clusters ==== Another application of direct insertion EI-MS is the characterization of novel synthetic carbon clusters isolated in the solid phase. These crystalline materials consist of C60 and C70 in the ratio of 37:1. In one investigation it has been shown that the synthetic C60 molecule is remarkably stable and that it retains its aromatic character.
Court docket: United States v. Carvajal-Barrios (S.D.N.Y.), 1:11-cr-00205; second superseding indictment against Maduro and others "Crisis in Venezuela". Frontline. Season 44. Episode 9. 10 February 2026. PBS. WGBH. Retrieved 25 February 2026.
Sources: en.wikipedia.org
No. It is not approved as a therapeutic drug by major regulators. It is sold for research purposes in many settings, which is not the same as clinical approval.
It is classified among peptide hormones and related substances that are prohibited in sport. The ban reflects anti-doping rules rather than a judgment that the peptide is effective for performance enhancement.
Human studies are limited and have not produced consistent evidence of meaningful clinical benefit. Some early trials examined metabolic endpoints, but larger confirmatory trials are generally lacking.
It is a synthetic peptide based on a C-terminal fragment of human growth hormone. It is commonly referred to as hGH fragment 176-191 and is studied for metabolic effects rather than growth effects.